Publications by authors named "Ana C C A Feldner"
Article Synopsis
- NS3 protease inhibitors (PIs) are key antiviral treatments for hepatitis C, particularly beneficial for patients with chronic kidney issues who cannot use interferon.
- A study assessed the prevalence of resistance-associated variants (RAVs) in 67 patients undergoing dialysis or renal transplants, finding that 18% had mutations affecting PIs, mostly in those with GT1a infection.
- Despite the presence of these low-resistance variants, the Q80K polymorphism was rare, suggesting that PIs can still be effectively used in this patient population.
Hepatitis C virus (HCV) infection is highly prevalent among chronic kidney disease (CKD) subjects under hemodialysis and in kidney transplantation (KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on management and treatment decisions.
View Article and Find Full Text PDF